EyePoint reports topline data from LUGANO Phase 3 DURAVYU 2.7mg trial
EyePoint (EYPT) announces topline data from LUGANO, the first of two pivotal Phase 3 trials for DURAVYU™ 2.7mg in wet AMD, with no additional figures provided.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.